You are here

Article info

Article menu
Download PDFPDF
Commentary
Pharmacological interventions
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia

Authors

  1. Correspondence to Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY 10595, USA; citrome{at}cnsconsultant.com
View Full Text

Citation

Citrome L
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia
Evidence-Based Mental Health 2018;21:e12.

Publication history

  • Received April 22, 2018
  • Revised May 17, 2018
  • Accepted May 17, 2018
  • First published June 26, 2018.
Online issue publication 
July 30, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.